Table 2.
Case No. | irAE | CTCAE Grade | Sex | Age, years | Cancer | Treatment | Systemic Steroid Use | Best Response |
---|---|---|---|---|---|---|---|---|
1 | Dermatitis | 3 | Male | 53 | Colorectal | Cytokine | No | PD |
| ||||||||
2 | Enterocolitis | 3 | Female | 49 | Colorectal | Checkpoint | Yes | SD |
| ||||||||
3 | LFT elevation | 3 | Male | 60 | GE junction | Combination | Yes | SD |
| ||||||||
4 | Dermatitis | 3 | Female | 48 | Cervical | Checkpoint | Yes | PD |
| ||||||||
5 | Enterocolitis | 4 | Male | 73 | Thyroid | Checkpoint | Yes | NE |
| ||||||||
6 | Autoimmune hepatitis | 3 | Male | 56 | NSCLC | Combination | Yes | PR |
| ||||||||
7 | Pleuritis (serositis) | 3 | Male | 66 | NSCLC | Cytokine | Yes | SD |
| ||||||||
8 | Myositis | 4 | Male | 66 | RCC | Checkpoint | Yes | NE |
Autoimmune hepatitis | 3 | Yes | ||||||
Myasthenia gravis | 3 | * IV Ig | ||||||
| ||||||||
9 | Myositis | 4 | Male | 59 | RCC | Checkpoint | Yes | PR |
| ||||||||
10 | Enterocolitis | 3 | Male | 70 | RCC | Combination | Yes | NE |
| ||||||||
11 | Pneumonitis | 3 | Female | 71 | Leiomyosarcoma | Vaccine | No | SD |
| ||||||||
12 | Dermatitis | 3 | Male | 58 | Adenoid cystic carcinoma | Cytokine | No | SD |
| ||||||||
13 | Dermatitis | 3 | Female | 75 | Hurthle cell carcinoma | Combination | Yes | PD |
| ||||||||
14 | Pancreatitis | 4 | Male | 59 | Neuroendocrine tumor | Combination | No | PD |
| ||||||||
15 | Myasthenia gravis | 3 | Male | 71 | Prostate | Checkpoint | Yes | CR |
Abbreviations: CTCAE, Common Terminology Criteria for Adverse Events; GE, gastroesophageal; IV Ig, intravenous immunoglobulin; LFT, liver function test; NE, Not evaluable; NSCLC, non-small cell lung carcinoma; RCC, renal cell carcinoma.
In addition to systemic corticosteroid, patient received intravenous immunoglobulin for myasthenia gravis.